Details

Autor(en) / Beteiligte

• Marquis-Gravel, Guillaume
• Roe, Matthew T
• Turakhia, Mintu P
• Boden, William
• Temple, Robert
• Sharma, Abhinav
• Hirshberg, Boaz
• Slater, Paul
• Craft, Noah
• Stockbridge, Norman
• McDowell, Bryan
• Waldstreicher, Joanne
• Bourla, Ariel
• Bansilal, Sameer
• Wong, Jennifer L
• Meunier, Claire
• Kassahun, Helina
• Coran, Philip
• Bataille, Lauren
• Patrick-Lake, Bray
• Hirsch, Brad
• Reites, John
• Mehta, Rajesh
• Muse, Evan D
• Chandross, Karen J
• Silverstein, Jonathan C
• Silcox, Christina
• Overhage, J Marc
• Califf, Robert M
• Peterson, Eric D

Titel

Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation

Ist Teil von

• Circulation (New York, N.Y.), 2019-10, Vol.140 (17), p.1426-1436

Ort / Verlag

by the American College of Cardiology Foundation and the American Heart Association, Inc

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• The complexity and costs associated with traditional randomized, controlled trials have increased exponentially over time, and now threaten to stifle the development of new drugs and devices. Nevertheless, the growing use of electronic health records, mobile applications, and wearable devices offers significant promise for transforming clinical trials, making them more pragmatic and efficient. However, many challenges must be overcome before these innovations can be implemented routinely in randomized, controlled trial operations. In October of 2018, a diverse stakeholder group convened in Washington, DC, to examine how electronic health record, mobile, and wearable technologies could be applied to clinical trials. The group specifically examined how these technologies might streamline the execution of clinical trial components, delineated innovative trial designs facilitated by technological developments, identified barriers to implementation, and determined the optimal frameworks needed for regulatory oversight. The group concluded that the application of novel technologies to clinical trials provided enormous potential, yet these changes needed to be iterative and facilitated by continuous learning and pilot studies.